According to Zhitong Finance APP, CUTIA-B (02487) rose over 14% in early trading, and as of the time of writing, it has increased by 14.24%, trading at HKD 10.91, with a transaction volume of HKD 29.0652 million.

In terms of news, CUTIA announced its interim results, reporting a 30.6% year-on-year decrease in revenue to approximately HKD 66.3 million for the first half of the year; the net loss was approximately HKD 239 million, an increase of about 19.1% year-on-year. The announcement stated that the revenue decline was mainly due to the group's prudent decision to terminate its agency cooperation with the American skincare brand OMA under the influence of macro policies and the international environment, reallocating resources to the commercialization preparations of new products such as CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam), which have already received regulatory approval. These new products are expected to have greater market potential and a higher return on investment, and this adjustment is anticipated to benefit the group's medium to long-term development.

In addition, CUTIA announced plans to issue a total of 28.904 million placement shares at a placement price of HKD 8.40 per share, representing a discount of approximately 12.04% compared to the closing price of HKD 9.55 per share on the previous trading day. The net proceeds from the placement are expected to be approximately HKD 240 million, with 45% allocated for preclinical research and development, clinical trials, and production facility layout in areas such as localized fat accumulation management, hair diseases and care, skin diseases and care, and epidermal anesthesia; another 45% will be used for market promotion, channel expansion, and brand building for CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam); the remaining 10% will be used for working capital and general corporate purposes